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 Introductions: Hepatitis C virus (HCV) infection is common in the patients 
undergoing hemodialysis (HD). The quality of life and survival of patients 
with hepatitis C infected end-stage renal disease is less than that of the 
noninfected ones. This study aims to determine the prevalence of HCV in 
patients undergoing HD and the risk of transmission. 
 
Methods: This was a retrospective study of charts of the chronic kidney 
disease patients who underwent dialysis at Patan Hospital from March 
2011 to July 2017. Those patients who were positive for HIV, HBsAg and 
HCV before the initiation of dialysis were excluded. Pearson Chi square 
test and Fisher’s Exact test were used to determine the significance of 
the results. 
 
Results: Out of 173 patients, 12 (6.9%) seroconverted to HCV: five 
(41.66%) in first year, four (33.33%) in second year, and three (25%) in 
third year (Fisher’s Exact test p=0.26). Out of 173 patients, 137 (79.2%) 
received blood transfusion, 27 (15.6%) received erythropoiesis 
stimulating agent (ESA), 9 (5.2%) received both blood transfusion and 
ESA. The HCV seropositivity were 9 (75%), 2 (16.66%), and 1 (8.33%) 
respectively in them, Fisher’s Exact test p value was 0.65. There was no 
significant association between the seroconversions in in-center versus 
multicenter HD and the number of dialyses per week. 
 
Conclusions: Hepatitis C infection was common (6.9%) in HD patients. 
There was no significant association of transmission in regards to 
duration of HD, transfusion or single vs multicentre HD. 
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According to the WHO, there are 30 million 
carriers of hepatitis C virus, 1.6% of 
population in the South-East Asia Region. 
There are 500,000 cases of viral hepatitis, 
cirrhosis and liver cancer, resulting in 120,000 
deaths annually. The HCV seroprevalence is 
highest in the intravenous (IV) drug users, 50-
100%.1 
 
The patients on hemodialysis (HD) are at 
higher risk for HCV infection, with the 
seroprevalence of 5-60%.2 Hepatitis C is the 
commonest cause of hepatitis in HD patients.3 
The HCV contaminated blood transfusion, de 
novo transmission, duration of HD are main 
risk factors.4-7  
 
The HCV infected persons on HD have a 
decreased quality of life and increased risk of 
mortality. The HCV infected renal transplant 
recipients have deleterious effect on 
transplant outcomes and reduced graft as 
well as patient survival.8 
 
The aim of the study was to assess the 
prevalence of hepatitis C and associated risk 





This was a retrospective study conducted at 
HD unit of Patan Hospital, Patan Academy of 
Health Sciences (PAHS), Nepal. Charts of the 
chronic kidney disease patients who had 
undergone maintenance dialysis were studied 
from March 2011 to July 2017, total of five 
years and four months. The serological test 
was conducted by using NANBASE C-96 V4.0 
test kit. It is a fourth generation enzyme 
immunoassay diagnostic kit. This test has 
sensitivity and specificity of 100% and 99.8% 
respectively. 
 
The inclusion criteria for the study were: 
• The patient in the end-stage renal disease 
(ESRD) needing a maintenance HD 
• The patients who had at least two 
documented serological tests of HCV, at 
least three months apart. 
• The first test done before the initiation of 
the HD having negative result 
 
The exclusion criteria for the study were: 
• Seropositivity for the Human 
Immunodeficiency Virus, Hepatitis B virus 
and Hepatitis C virus infections before the 
commencement of the HD 
• Patients with acute renal failure needing 
the renal replacement therapy. 
• If the duration of HD could not be 
assessed. 
 
The following variables were studied: age, sex, 
address, duration of HD in months, receiving 
blood transfusions and/or erythropoiesis 
stimulating agents (ESA), number of HD 
sessions, single center or multi center dialysis 
were noted; (these were the patients who 
had received HD from another center. 
 
SPSS 20 was used for data analysis. Pearson 
Chi square test and Fishers exact test of 
independence was used to measure the 





There were 193 ESRD patients who 
underwent HD. Twenty patients were 
excluded and data on remaining 173 were 
analysed (Figure 1). Median age was 52 years 
(range 16-80 years), 97 male and 76 female 
(male to female ratio was 1.278). The point 
prevalence of hepatitis C seropositive was 
6.9%.  
 
Nine patients underwent renal 
transplantation; five in the first year, three in 
second year and one in the fourth year. Four 
got transferred out to another center; one in 
first year and three in second year of 
enrolment to dialysis. Most of the patients, 73 
(42.20%) were from Lalitpur district, Nepal. 
Eighty-six patients underwent dialysis 
treatment for up to one year duration, 50 for 
up to two years, 20 for 3 years, nine for 4 
years, six patients for 5 years and 2 for more 
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One hundred thirty-seven (79.20%) patients 
received blood transfusion only, 27 (15.60%) 
ESA and 9 (5.20%) received both blood 
transfusion as well as ESA. 
 
Among the patients with chronic kidney 
disease, 86 (49.71%) were dialysed in our 
center only, 53 (30.63%) received initial 
management from another center and later 
from our unit and for remaining 34 (19.65%), 
it was not clear whether they received their 
initial dialysis in our center or another center. 
 
Twelve (6.9%) patients seroconverted during 
the study period, 5 females and 7 males. Five  
 
 
(41.66%) seroconverted within one year of 
enrolment to the HD treatment, four (33.33%) 
during the second year and three (25%) 
during the third year. Prevalence of HCV 
seropositivity during the first year of initiation 
of HD was 2.89% (5 of 173), second year 
4.59% and third year 8.10% (Figure 2); Fisher’s 
Exact test showed p value of 0.26. 
 
 Out of the total 12 seropositive patients, nine 
(75%) had blood transfusion, 2 (16.66%) ESA 
and 1 (8.33%) had both ESA and blood 
transfusion. The prevalence of HCV 
seropositivity in the patients receiving blood 
transfusion, ESA， ESA and blood were 9/137 
Total number of  patients 193
Patients included in the study-173
Median age 52 years
Male:Female ratio 1.278
Excluded-20
Duration of HD unknown-5
Only single documented test-13
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(6.6%), 2/27 (7.4%) and 1/9 (11.11%), 
respectively, p value (Fisher’s Exact test) was 
0.65, (Figure 3). 
 
The seropositivity was seen in 6/86 (6.97%) 
who received HD in our center only; 6/53 
(11.32%) had HD in our as well as other 
centers also, (Pearson Chi square=0.849, df=1, 
p=0.356). Using a Fisher’s Exact test, p=0.53. 
(Figure 4). 
 
In our center 32 (18.50%) patients received 
once a week HD, 133 (76.88%) twice a week, 
and 8 (4.62%) thrice a week. The number of 
patients with seroconversion were 3 (9.37%) 
in once a week HD group, 7 (5.26%) in twice a 
week HD group and 2 (25%) in thrice a week 
HD group, Fisher’s Exact test showed the p 
value of 0.068,w (Figure 5). 
 
Out of 173 patients, 80 (46.24%) dropped out 
of HD by the end of the first year, 44/87 
(50.57%) by the end of 2ndyear, and 20/37 
(54.05%) by the end 3rdyear. The cause of 
drop out was not known, possibly lost to 












The point prevalence of hepatitis C 
seropositivity during HD in our study was 6.9% 
(12/173), which is higher than in a healthy 
general population 0.6%,9 blood donors 0.39-
0.66% 10,11and people living with HIV AIDS 
3.703%.10 However, this is less than in the 
intravenous drug users (IDU), 94%.9 The 
seroprevalence of Hepatitis C in patients 
receiving HD in northern and western 
India13,14 is reported to be 23% and 2.7% 
respectively and in Pakistan15 29.2%. In a 
systematic review from Middle-East, the 
highest prevalence was seen in Syria (54%) 
and Egypt (50%), lowest in Iran (12%) and 
Lebanon (9%).16 However, in a prospective 
study at two centers in Kathmandu, Nepal, 
during 2005-2006, there was no 
seroconversion reported.17  
 
In a multicenter study involving 2796 patients 
in Germany, the hepatitis C prevalence was 
7%. HCV seropositive was found in 6.1% of the 
patients but in 0.8 % of the patients the HCV 
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In our study, most of the infections occurred 
during the first year of HD, similar to the 
multicenter German study.18 They also 
reported increased prevalence with HD, but in 
subgroup analysis the duration of dialysis was 
not significantly associated with the HCV 
viremia.18 The Northern Indian study however 
reported duration of HD as an independent 
risk factor for acquiring Hepatitis C infection; 
85.4±23.7 sessions of HD in seropositive 
patients against 60.1±14.7 sessions in 
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In our study, 75% of patients with 
seroconversion had blood transfusion. Our 
study did not show blood transfusion and ESA 
as a risk factor or protection against HCV 
positivity. It may be due to the small sample 
size. In the German study, the prevalence of 
the hepatitis C increased statistically with the 
increase in number of blood transfusions, the 
highest being in the patients with more than 
five transfusions. But it was not significantly 
associated with the patients with HCV 
viremia. The sub group analysis did not find 
blood transmission to be significantly 
associated with it.18 
 
Our study showed that there is an increased 
risk for HCV seropositivity in the patients who 
had received HD in more than one center, 
though it was not statistically significant. 
There was no statistically significant increase 
in risk of acquiring hepatitis C with increased 
frequency of HD. Thus, less risk of nosocomial 
spread of infection. 
 
Due to small sample size, we could not 
establish the statistical significance for any 
risk factors of transmission of hepatitis C in 
HD unit. We also could not explain why there 
was a high seroprevalence of hepatitis C at 
first year of initiation of HD, possibly patients 
were incubating the disease prior to the 
initiation of HD. 
 
The number of patients who dropped out in 
our study was high, either due to loss to 
follow up or demise of the patient. In the 
study conducted in India, it showed a 
mortality rate of 54.04% on first year of 
dialysis treatment.19 In another 5 year study 
done in India, the mortality rate was higher in 
diabetic ESRD patient than in nondiabetic 
ESRD, at 47.76% and 33.80% respectively.20 
The percentage of mortality rate and loss to 
follow combined were also very high reaching 
73.43% in the diabetic patients and 60.14% in 
the nondiabetic in the study.20 
 
The limitations of our study were small 
sample size, relying on the antibody test only, 
as we could not perform the Polymerase 
Chain Reaction test to detect the hepatitis 
virus in the blood stream or genotyping for 
viremia. This is because, they denied for these 





Patients undergoing HD had low (6.9%) 
serocoversion for hepatitis C. There was no 
significant association of transmission in 
regards to duration of HD, transfusion or 
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